NCT05870475View on ClinicalTrials.gov

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

March 31, 2028

Study Completion Date

May 31, 2028

Conditions
Polycythemia Vera
Interventions
DRUG

Ruxolitinib

Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.

DRUG

Pegylated interferon α-2b

Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER